$ADAPY Cashflow Statement | Understand Stock

$ADAPY

$0.03 +$0.00 (3.08%) Close

$ADAPY Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Amortization
Impairment of long-lived assets
Gain on bargain purchase
Share-based compensation expense
Unrealized foreign exchange losses
Amortization (accretion) of available-for-sale debt securities
Other
Changes in operating assets and liabilities:
Decrease/(increase) in receivables and other operating assets
Increase in inventories
Increase in non-current assets
Increase/(decrease) in payables and other current liabilities
Increase in borrowings and other non-current liabilities
Net cash used in operating activities
Cash flows from investing activities
Acquisition of property, plant and equipment
Acquisition of intangible assets
Cash from acquisition of TCR2 Therapeutics Inc.
Maturity or redemption of marketable securities
Investment in marketable securities
Other
Net cash (used in)/provided by investing activities
Cash flows from financing activities
Proceeds from issuance of borrowings, net of discount
Proceeds from issuance of common stock from offerings, net of commissions and issuance costs
January Offering
June Offering
Over Allotment January
Over Allotment June
Total proceeds from issuance of common stock from offerings, net of commissions and issuance costs

Proceeds from exercise of stock options
Net cash provided by financing activities
Effect of currency exchange rate changes on cash, cash equivalents and restricted cash
Net decrease in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at start of period
Cash, cash equivalents and restricted cash at end of period
Supplemental cash flow information
Interest received
Interest Paid
Accretion/(amortization) on available-for-sale debt securities
Income taxes paid

Comments